RxDoctor Payments Data

Meilin Diaz-Paez

Family · Miami, FLNPI 1033539333

Payments from drug & device makers

$8,313in general payments, 2019–2025

Across 62 payments — averaging $134.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$5K
  • Legend Biotech USA Inc.$1K
  • Kadmon Pharmaceuticals LLC$1K
  • Incyte Corporation$355
  • Astellas Pharma US Inc$303
  • Merck$45
  • plus $173 from 6 others

What the payments were for

  • Consulting fees$1,89823%
  • Speaking & faculty fees$4,06949%
  • Travel & lodging$4766%
  • Food & beverage$1,32816%
  • Education$5437%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,313 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$2,396
Medicare patients
14
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate67$1,115,840
RezurockBelumosudil Mesylate16$274,862
CresembaIsavuconazonium Sulfate23$142,588
PrevymisLetermovir14$109,217
EliquisApixaban30$20,432
JardianceEmpagliflozin19$17,097
RestasisCyclosporine18$10,110
Atovaquone12$5,971
Cyclosporine13$4,346
Wixela InhubFluticasone Propion/Salmeterol39$3,107
Acyclovir60$1,034
ValacyclovirValacyclovir Hcl14$685
Rosuvastatin Calcium56$542
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim46$472
Gabapentin24$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$355$1,115,84067 claims
Sanofi-aventis U.S. LLCRezurock$5,209$274,86216 claims
Astellas Pharma US IncCresemba$303$142,58823 claims
MerckPrevymis$45$109,21714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →